Current Perspectives on Biological Therapy for COPD

References

• López-Campos JL, Tan W, Soriano JB. Global burden of COPD. Respirology. 2016;21(1):14–23. DOI:10.1111/resp.12660
   PubMed Web of Science ®Google Scholar
• Chung KF, Adcock IM. Multifaceted mechanisms in COPD: inflammation, immunity, and tissue repair and destruction. Eur Respir J. 2008;31(6):1334–1356. DOI:10.1183/09031936.00018908
   PubMed Web of Science ®Google Scholar
• Burrows B, Knudson RJ, Cline MG, et al. Quantitative relationships between cigarette smoking and ventilatory function. Am Rev Respir Dis. 1977;115(2):195–205.
   PubMed Web of Science ®Google Scholar
• Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary. Am J Respir Crit Care Med. 2017;195(5):557–582. DOI:10.1164/rccm.201701-0218PP
   PubMed Web of Science ®Google Scholar
• Agustí A, Celli B, Faner R. What does endotyping mean for treatment in chronic obstructive pulmonary disease? Lancet. 2017;390(10098):980–987. DOI:10.1016/S0140-6736(17)32136-0
   PubMed Web of Science ®Google Scholar
• Castaldi PJ, Benet M, Petersen H, et al. Do COPD subtypes really exist? COPD heterogeneity and clustering in 10 independent cohorts. Thorax. 2017;72(11):998–1006.
   PubMed Web of Science ®Google Scholar
• Pauwels RA, Löfdahl C-G, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European respiratory society study on chronic obstructive pulmonary disease. N Engl J Med. 1999;340(25):1948–1953. DOI:10.1056/NEJM199906243402503
   PubMed Web of Science ®Google Scholar
• Culpitt S, Maziak W, Loukidis S, et al. Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999;160(5):1635–1639. DOI:10.1164/ajrccm.160.5.9811058
   PubMed Web of Science ®Google Scholar
• Matera MG, Cardaci V, Cazzola M, et al. Safety of inhaled corticosteroids for treating chronic obstructive pulmonary disease. Expert Opin Drug Saf. 2015;14(4):533–541. DOI:10.1517/14740338.2015.1001363
   PubMed Web of Science ®Google Scholar
• Saetta M, Turato G, Maestrelli P, et al. Cellular and structural bases of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;163(6):1304–1309. DOI:10.1164/ajrccm.163.6.2009116
   PubMed Web of Science ®Google Scholar
• O'Shaughnessy TC, Ansari TW, Barnes NC, et al. Inflammation in bronchial biopsies of subjects with chronic bronchitis: inverse relationship of CD8+ T lymphocytes with FEV1. Am J Respir Crit Care Med. 1997;155(3):852–857. DOI:10.1164/ajrccm.155.3.9117016
   PubMed Web of Science ®Google Scholar
• Saetta M, Di STEFANO A, Turato G, et al. CD8+ T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157(3):822–826. DOI:10.1164/ajrccm.157.3.9709027
   PubMed Web of Science ®Google Scholar
• Saetta M, Baraldo S, Corbino L, et al. CD8 + ve cells in the lungs of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999;160(2):711–717. DOI:10.1164/ajrccm.160.2.9812020
   PubMed Web of Science ®Google Scholar
• Saetta M, et al. Increased proportion of CD8+ T-lymphocytes in the paratracheal lymph nodes of smokers with mild COPD. Sarcoidosis Vasculitis Diffuse Lung Dis. 2003;20(1):28–32.
   PubMed Web of Science ®Google Scholar
• Di Stefano A, Capelli A, Lusuardi M, et al. Severity of airflow limitation is associated with severity of airway inflammation in smokers. Am J Respir Crit Care Med. 1998;158(4):1277–1285.
   PubMed Web of Science ®Google Scholar
• Maestrelli P, Saetta M, Mapp CE, et al. Remodeling in response to infection and injury. Airway inflammation and hypersecretion of mucus in smoking subjects with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164(10 Pt 2):S76–S80.
   PubMed Web of Science ®Google Scholar
• Brusselle GG, Joos GF, Bracke KR. New insights into the immunology of chronic obstructive pulmonary disease. Lancet. 2011;378(9795):1015–1026.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol. 2008;8(3):183–192. DOI:10.1038/nri2254
   PubMed Web of Science ®Google Scholar
• Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(26):2645–2653. DOI:10.1056/NEJMoa032158
   PubMed Web of Science ®Google Scholar
• Givi ME, et al. Dendritic cells in pathogenesis of COPD. Curr Pharm Des. 2012;18(16):2329–2335.
   PubMed Web of Science ®Google Scholar
• Stockley RA. Neutrophils and protease/antiprotease imbalance. Am J Respir Crit Care Med. 1999;160(supplement_1):S49–S52. DOI:10.1164/ajrccm.160.supplement_1.13
   PubMedGoogle Scholar
• Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J. 2003;22(4):672–688. DOI:10.1183/09031936.03.00040703
   PubMed Web of Science ®Google Scholar
• Frasca L, Lande R. Role of defensins and cathelicidin LL37 in auto-immune and auto-inflammatory diseases. CPB. 2012;13(10):1882–1897. DOI:10.2174/138920112802273155
   Google Scholar
• Paone G, Conti V, Vestri A, et al. Analysis of sputum markers in the evaluation of lung inflammation and functional impairment in symptomatic smokers and COPD patients. Dis Markers. 2011;31(2):91–100. DOI:10.1155/2011/139493
   PubMed Web of Science ®Google Scholar
• Overbeek SA, Braber S, Koelink PJ, et al. Cigarette smoke-induced collagen destruction; key to chronic neutrophilic airway inflammation? PLoS One. 2013;8(1):e55612. DOI:10.1371/journal.pone.0055612
   PubMed Web of Science ®Google Scholar
• Peleman RA, Rytilä PH, Kips JC, et al. The cellular composition of induced sputum in chronic obstructive pulmonary disease. Eur Respir J. 1999;13(4):839–843. DOI:10.1034/j.1399-3003.1999.13d24.x
   PubMed Web of Science ®Google Scholar
• Keatings VM, Collins PD, Scott DM, et al. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med. 1996;153(2):530–534. DOI:10.1164/ajrccm.153.2.8564092
   PubMed Web of Science ®Google Scholar
• Cheronis JC, Whalley ET, Nguyen KT, et al. A new class of bradykinin antagonists: synthesis and in vitro activity of bissuccinimidoalkane peptide dimers. J Med Chem. 1992;35(9):1563–1572.
   PubMed Web of Science ®Google Scholar
• Kreisle RA, Parker CW. Specific binding of leukotriene B4 to a receptor on human polymorphonuclear leukocytes. J Exp Med. 1983;157(2):628–641. DOI:10.1084/jem.157.2.628
   PubMed Web of Science ®Google Scholar
• Reilly IA, Knapp HR, Fitzgerald GA. Leukotriene B4 synthesis and neutrophil chemotaxis in chronic granulocytic leukaemia. J Clin Pathol. 1988;41(11):1163–1167. DOI:10.1136/jcp.41.11.1163
   PubMed Web of Science ®Google Scholar
• Barnett ML, Lamb KA, Costello KM, et al. Characterization of interleukin-8 receptors in human neutrophil membranes: regulation by guanine nucleotides. Biochim Biophys Acta. 1993;1177(3):275–282.
   PubMedGoogle Scholar
• Kobayashi SD, et al. Neutrophils in the innate immune response. Arch Immunol Ther Exp (Warsz). 2005;53(6):505–517.
   PubMed Web of Science ®Google Scholar
• Kobayashi SD, DeLeo FR. Role of neutrophils in innate immunity: a systems biology-level approach. WIREs Mech Dis. 2009;1(3):309–333. DOI:10.1002/wsbm.32
   Google Scholar
• Negewo N, McDonald V, Baines K, et al. Peripheral blood eosinophils: a surrogate marker for airway eosinophilia in stable COPD. COPD. 2016;ume 11:1495–1504. DOI:10.2147/COPD.S100338
   Google Scholar
• Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med. 2011;184(6):662–671.
   PubMed Web of Science ®Google Scholar
• Singh D, Kolsum U, Brightling CE, et al. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur Respir J. 2014;44(6):1697–1700. DOI:10.1183/09031936.00162414
   PubMed Web of Science ®Google Scholar
• Kolsum U, Damera G, Pham T-H, et al. Pulmonary inflammation in patients with chronic obstructive pulmonary disease with higher blood eosinophil counts. J Allergy Clin Immunol. 2017;140(4):1181–1184.e7. DOI:10.1016/j.jaci.2017.04.027
   PubMed Web of Science ®Google Scholar
• Lindemans CA, Kimpen JLL, Luijk B, et al. Systemic eosinophil response induced by respiratory syncytial virus. Clin Exp Immunol. 2006;144(3):409–417. DOI:10.1111/j.1365-2249.2006.03084.x
   PubMed Web of Science ®Google Scholar
• Davoine F, Lacy P. Eosinophil cytokines, chemokines, and growth factors: emerging roles in immunity. Front Immunol. 2014;5:570.
   PubMed Web of Science ®Google Scholar
• George L, Brightling CE. Eosinophilic airway inflammation: role in asthma and chronic obstructive pulmonary disease. Ther Adv Chronic Dis. 2016;7(1):34–51. DOI:10.1177/2040622315609251
   PubMed Web of Science ®Google Scholar
• Conroy DM, Williams TJ. Eotaxin and the attraction of eosinophils to the asthmatic lung. Respir Res. 2001;2(3):150–156. DOI:10.1186/rr52
   PubMed Web of Science ®Google Scholar
• Smit JJ, Lukacs NW. A closer look at chemokines and their role in asthmatic responses. Eur J Pharmacol. 2006;533(1-3):277–288. DOI:10.1016/j.ejphar.2005.12.064
   PubMed Web of Science ®Google Scholar
• Moermans C, Bonnet C, Willems E, et al. Sputum cytokine levels in patients undergoing hematopoietic SCT and comparison with healthy subjects and COPD: a pilot study. Bone Marrow Transplant. 2014;49(11):1382–1388. DOI:10.1038/bmt.2014.164
   PubMed Web of Science ®Google Scholar
• Balzano G, Stefanelli F, Iorio C, et al. Eosinophilic inflammation in stable chronic obstructive pulmonary disease. Relationship with neutrophils and airway function. Am J Respir Crit Care Med. 1999;160(5):1486–1492. DOI:10.1164/ajrccm.160.5.9810105
   PubMed Web of Science ®Google Scholar
• Moermans C, Heinen V, Nguyen M, et al. Local and systemic cellular inflammation and cytokine release in chronic obstructive pulmonary disease. Cytokine. 2011;56(2):298–304. DOI:10.1016/j.cyto.2011.07.010
   PubMed Web of Science ®Google Scholar
• Siddiqui SH, Guasconi A, Vestbo J, et al. Blood eosinophils: a biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;192(4):523–525. DOI:10.1164/rccm.201502-0235LE
   PubMed Web of Science ®Google Scholar
• Vedel-Krogh S, Nielsen SF, Lange P, et al. Blood eosinophils and exacerbations in chronic obstructive pulmonary disease. The copenhagen general population study. Am J Respir Crit Care Med. 2016;193(9):965–974. DOI:10.1164/rccm.201509-1869OC
   PubMed Web of Science ®Google Scholar
• Patel VA, Longacre A, Hsiao K, et al. Apoptotic cells, at all stages of the death process, trigger characteristic signaling events that are divergent from and dominant over those triggered by necrotic cells: implications for the delayed clearance model of autoimmunity. J Biol Chem. 2006;281(8):4663–4670.
   PubMed Web of Science ®Google Scholar
• Johann AM, von Knethen A, Lindemann D, et al. Recognition of apoptotic cells by macrophages activates the peroxisome proliferator-activated receptor-gamma and attenuates the oxidative burst. Cell Death Differ. 2006;13(9):1533–1540. DOI:10.1038/sj.cdd.4401832
   PubMed Web of Science ®Google Scholar
• Vandivier RW, Henson PM, Douglas IS. Burying the dead: the impact of failed apoptotic cell removal (efferocytosis) on chronic inflammatory lung disease. Chest. 2006;129(6):1673–1682. DOI:10.1378/chest.129.6.1673
   PubMed Web of Science ®Google Scholar
• Chamoto K, Gibney BC, Ackermann M, et al. Alveolar macrophage dynamics in murine lung regeneration. J Cell Physiol. 2012;227(9):3208–3215. DOI:10.1002/jcp.24009
   PubMed Web of Science ®Google Scholar
• Lolmede K, Campana L, Vezzoli M, et al. Inflammatory and alternatively activated human macrophages attract vessel-associated stem cells, relying on separate HMGB1- and MMP-9-dependent pathways. J Leukoc Biol. 2009;85(5):779–787. DOI:10.1189/jlb.0908579
   PubMed Web of Science ®Google Scholar
• MacNee W. Pathogenesis of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005;2(4):258–266. discussion 290–1. DOI:10.1513/pats.200504-045SR
   PubMedGoogle Scholar
• Aldonyte R, Jansson L, Piitulainen E, et al. Circulating monocytes from healthy individuals and COPD patients. Respir Res. 2003;4(1):11. DOI:10.1186/1465-9921-4-11
   PubMedGoogle Scholar
• Hogg JC, Timens W. The pathology of chronic obstructive pulmonary disease. Annu Rev Pathol Mech Dis. 2009;4(1):435–459. DOI:10.1146/annurev.pathol.4.110807.092145
   PubMed Web of Science ®Google Scholar
• Caramori G, Casolari P, Giuffrè S, et al. COPD pathology in the small airways. Panminerva Med. 2011;53(1):51–70.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Cellular and molecular mechanisms of chronic obstructive pulmonary disease. Clin Chest Med. 2014;35(1):71–86. DOI:10.1016/j.ccm.2013.10.004
   PubMed Web of Science ®Google Scholar
• Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet. 2004;364(9435):709–721. DOI:10.1016/S0140-6736(04)16900-6
   PubMed Web of Science ®Google Scholar
• Enelow RI, Mohammed AZ, Stoler MH, et al. Structural and functional consequences of alveolar cell recognition by CD8(+) T lymphocytes in experimental lung disease. J Clin Invest. 1998;102(9):1653–1661. DOI:10.1172/JCI4174
   PubMed Web of Science ®Google Scholar
• Grumelli S, Corry DB, Song L-Z, et al. An immune basis for lung parenchymal destruction in chronic obstructive pulmonary disease and emphysema. PLoS Med. 2004;1(1):e8. DOI:10.1371/journal.pmed.0010008
   PubMed Web of Science ®Google Scholar
• Pizzichini E, Pizzichini MM, Gibson P, et al. Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis. Am J Respir Crit Care Med. 1998;158(5 Pt 1):1511–1517.
   PubMed Web of Science ®Google Scholar
• Brightling CE. Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax. 2005;60(3):193–198. DOI:10.1136/thx.2004.032516
   PubMed Web of Science ®Google Scholar
• Brightling CE, Monteiro W, Ward R, et al. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2000;356(9240):1480–1485. DOI:10.1016/S0140-6736(00)02872-5
   PubMed Web of Science ®Google Scholar
• Page C, Cazzola M. Bifunctional drugs for the treatment of asthma and chronic obstructive pulmonary disease. Eur Respir J. 2014;44(2):475–482. DOI:10.1183/09031936.00003814
   PubMed Web of Science ®Google Scholar
• Matera MG, Page CP, Calzetta L, et al. Pharmacology and therapeutics of bronchodilators revisited. Pharmacol Rev. 2020;72(1):218–252. DOI:10.1124/pr.119.018150
   PubMed Web of Science ®Google Scholar
• Mio T, Romberger DJ, Thompson AB, et al. Cigarette smoke induces interleukin-8 release from human bronchial epithelial cells. Am J Respir Crit Care Med. 1997;155(5):1770–1776. DOI:10.1164/ajrccm.155.5.9154890
   PubMed Web of Science ®Google Scholar
• Sakao S, Tatsumi K, Igari H, Association of Non-University-Affiliated Pulmonary Specialist Physicians of Chiba University School of Medicine, et al. Association of tumor necrosis factor α gene promoter polymorphism with the presence of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;163(2):420–422. DOI:10.1164/ajrccm.163.2.2006031
   PubMed Web of Science ®Google Scholar
• Churg A, Wang RD, Tai H, et al. Tumor necrosis factor-alpha drives 70% of cigarette smoke-induced emphysema in the mouse. Am J Respir Crit Care Med. 2004;170(5):492–498. DOI:10.1164/rccm.200404-511OC
   PubMed Web of Science ®Google Scholar
• Mulligan MS, Polley MJ, Bayer RJ, et al. Neutrophil-dependent acute lung injury. Requirement for P-selectin (GMP-140). J Clin Invest. 1992;90(4):1600–1607.
   PubMed Web of Science ®Google Scholar
• Di Stefano A, Maestrelli P, Roggeri A, et al. Upregulation of adhesion molecules in the bronchial mucosa of subjects with chronic obstructive bronchitis. Am J Respir Crit Care Med. 1994;149(3 Pt 1):803–810.
   PubMed Web of Science ®Google Scholar
• Wu AJ, Chen ZJ, Tsokos M, et al. Interferon-gamma induced cell death in a cultured human salivary gland cell line. J Cell Physiol. 1996;167(2):297–304. DOI:10.1002/(SICI)1097-4652(199605)167:2<297::AID-JCP14>3.0.CO;2-5
   PubMed Web of Science ®Google Scholar
• Miyazaki Y, Araki K, Vesin C, et al. Expression of a tumor necrosis factor-alpha transgene in murine lung causes lymphocytic and fibrosing alveolitis. A mouse model of progressive pulmonary fibrosis. J Clin Invest. 1995;96(1):250–259. DOI:10.1172/JCI118029
   PubMed Web of Science ®Google Scholar
• Kampf C, Relova AJ, Sandler S, et al. Effects of TNF-alpha, IFN-gamma and IL-beta on normal human bronchial epithelial cells. Eur Respir J. 1999;14(1):84–91.
   PubMed Web of Science ®Google Scholar
• Takeyama K, Jung B, Shim JJ, et al. Activation of epidermal growth factor receptors is responsible for mucin synthesis induced by cigarette smoke. Am J Physiol Lung Cell Mol Physiol. 2001;280(1):L165–72. p.
   PubMed Web of Science ®Google Scholar
• Yilmaz O, Karaman M, Bagriyanik HA, et al. Comparison of TNF antagonism by etanercept and dexamethasone on airway epithelium and remodeling in an experimental model of asthma. Int Immunopharmacol. 2013;17(3):768–773. DOI:10.1016/j.intimp.2013.08.021
   PubMed Web of Science ®Google Scholar
• Dejager L, Dendoncker K, Eggermont M, et al. Neutralizing TNFα restores glucocorticoid sensitivity in a mouse model of neutrophilic airway inflammation. Mucosal Immunology. 2015;8(6):1212–1225. DOI:10.1038/mi.2015.12
   PubMed Web of Science ®Google Scholar
• van der Vaart H, Koëter GH, Postma DS, et al. First study of infliximab treatment in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;172(4):465–469.
   PubMed Web of Science ®Google Scholar
• Dentener MA, Creutzberg EC, Pennings H-J, et al. Effect of infliximab on local and systemic inflammation in chronic obstructive pulmonary disease: a pilot study. Respiration. 2008;76(3):275–282. DOI:10.1159/000117386
   PubMed Web of Science ®Google Scholar
• Rennard SI, Fogarty C, Kelsen S, et al. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175(9):926–934. DOI:10.1164/rccm.200607-995OC
   PubMed Web of Science ®Google Scholar
• Suissa S, Ernst P, Hudson M. TNF-alpha antagonists and the prevention of hospitalisation for chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2008;21(1):234–238. DOI:10.1016/j.pupt.2007.03.003
   PubMed Web of Science ®Google Scholar
• Aaron SD, Vandemheen KL, Maltais F, et al. TNFα antagonists for acute exacerbations of COPD: a randomised double-blind controlled trial. Thorax. 2013;68(2):142–148. DOI:10.1136/thoraxjnl-2012-202432
   PubMed Web of Science ®Google Scholar
• Muraguchi A, Hirano T, Tang B, et al. The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells. J Exp Med. 1988;167(2):332–344.
   PubMed Web of Science ®Google Scholar
• Park JY, Pillinger MH. Interleukin-6 in the pathogenesis of rheumatoid arthritis. Bull NYU Hosp Jt Dis. 2007;65 Suppl 1(Suppl 1):S4–S10.
   PubMedGoogle Scholar
• Kim V, Rogers TJ, Criner GJ. New concepts in the pathobiology of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2008;5(4):478–485. DOI:10.1513/pats.200802-014ET
   PubMedGoogle Scholar
• Hageman GJ. Systemic poly(ADP-ribose) polymerase-1 activation, chronic inflammation, and oxidative stress in COPD patients. Free Radic Biol Med. 2003;35(2):140–148. DOI:10.1016/S0891-5849(03)00237-5
   PubMed Web of Science ®Google Scholar
• Godoy I, Campana AO, Geraldo RRC, et al. Cytokines and dietary energy restriction in stable chronic obstructive pulmonary disease patients. Eur Respir J. 2003;22(6):920–925. DOI:10.1183/09031936.03.00025303
   PubMed Web of Science ®Google Scholar
• Debigaré R, Marquis K, Côté CH, et al. Catabolic/anabolic balance and muscle wasting in patients with COPD. Chest. 2003;124(1):83–89. DOI:10.1378/chest.124.1.83
   PubMed Web of Science ®Google Scholar
• Bucchioni E, Kharitonov SA, Allegra L, et al. High levels of interleukin-6 in the exhaled breath condensate of patients with COPD. Respir Med. 2003;97(12):1299–1302. DOI:10.1016/j.rmed.2003.07.008
   PubMed Web of Science ®Google Scholar
• Weidong S, et al. Interleukin-6 in bronchoalveolar lavage fluid from patients with COPD. Chin Med J. 2001;114(11):1140–1142.
   PubMed Web of Science ®Google Scholar
• Bhowmik A, Seemungal TA, Sapsford RJ, et al. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax. 2000;55(2):114–120.
   PubMed Web of Science ®Google Scholar
• Arenberg DA, Kunkel SL, Polverini PJ, et al. Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice. J Clin Invest. 1996;97(12):2792–2802. DOI:10.1172/JCI118734
   PubMed Web of Science ®Google Scholar
• Strieter RM, et al. Interleukin-8. A corneal factor that induces neovascularization. Am J Pathol. 1992;141(6):1279–1284.
   PubMed Web of Science ®Google Scholar
• Traves SL. Increased levels of the chemokines GROalpha and MCP-1 in sputum samples from patients with COPD. Thorax. 2002;57(7):590–595. DOI:10.1136/thorax.57.7.590
   PubMed Web of Science ®Google Scholar
• Soler N, Ewig S, Torres A, et al. Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease. Eur Respir J. 1999;14(5):1015–1022.
   PubMed Web of Science ®Google Scholar
• Adage T, del Bene F, Fiorentini F, et al. PA401, a novel CXCL8-based biologic therapeutic with increased glycosaminoglycan binding, reduces bronchoalveolar lavage neutrophils and systemic inflammatory markers in a murine model of LPS-induced lung inflammation. Cytokine. 2015;76(2):433–441. DOI:10.1016/j.cyto.2015.08.006
   PubMed Web of Science ®Google Scholar
• Mahler DA, Huang S, Tabrizi M, et al. Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: a pilot study. Chest. 2004;126(3):926–934. DOI:10.1378/chest.126.3.926
   PubMed Web of Science ®Google Scholar
• Rennard SI, Dale DC, Donohue JF, et al. CXCR2 antagonist MK-7123. A phase 2 proof-of-Concept trial for chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;191(9):1001–1011. DOI:10.1164/rccm.201405-0992OC
   PubMed Web of Science ®Google Scholar
• Kirsten AM, Förster K, Radeczky E, et al. The safety and tolerability of oral AZD5069, a selective CXCR2 antagonist, in patients with moderate-to-severe COPD. Pulm Pharmacol Ther. 2015;31:36–41. DOI:10.1016/j.pupt.2015.02.001
   PubMed Web of Science ®Google Scholar
• Bartlett HS, Million RP. Targeting the IL-17-T(H)17 pathway. Nat Rev Drug Discov. 2015;14(1):11–12. DOI:10.1038/nrd4518
   PubMed Web of Science ®Google Scholar
• Chang Y, Al-Alwan L, Audusseau S, et al. Genetic deletion of IL-17A reduces cigarette smoke-induced inflammation and alveolar type II cell apoptosis. Am J Physiol Lung Cell Mol Physiol. 2014;306(2):L132–L143. p. DOI:10.1152/ajplung.00111.2013
   PubMed Web of Science ®Google Scholar
• Roos AB, Sethi S, Nikota J, et al. IL-17A and the promotion of neutrophilia in acute exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;192(4):428–437. DOI:10.1164/rccm.201409-1689OC
   PubMed Web of Science ®Google Scholar
• Shen N, Wang J, Zhao M, et al. Anti-interleukin-17 antibodies attenuate airway inflammation in tobacco-smoke-exposed mice. Inhal Toxicol. 2011;23(4):212–218. DOI:10.3109/08958378.2011.559603
   PubMed Web of Science ®Google Scholar
• Kirsten A, Watz H, Pedersen F, et al. The anti-IL-17A antibody secukinumab does not attenuate ozone-induced airway neutrophilia in healthy volunteers. Eur Respir J. 2013;41(1):239–241. DOI:10.1183/09031936.00123612
   PubMed Web of Science ®Google Scholar
• Eich A, Urban V, Jutel M, et al. A randomized, Placebo-Controlled phase 2 trial of CNTO 6785 in chronic obstructive pulmonary disease. COPD. 2017;14(5):476–483. DOI:10.1080/15412555.2017.1335697
   PubMedGoogle Scholar
• Matera MG, Cazzola M, Page C. Prospects for COPD treatment. Curr Opin Pharmacol. 2021;56:74–84. DOI:10.1016/j.coph.2020.11.003
   PubMed Web of Science ®Google Scholar
• Rosenberg HF, Dyer KD, Foster PS. Eosinophils: changing perspectives in health and disease. Nat Rev Immunol. 2013;13(1):9–22. DOI:10.1038/nri3341
   PubMed Web of Science ®Google Scholar
• Caramori G, et al. Cytokine inhibition in the treatment of COPD. Int J Chron Obstruct Pulmon Dis. 2014;9:397–412.
   PubMed Web of Science ®Google Scholar
• Eltboli O, Mistry V, Barker B, et al. Relationship between blood and bronchial submucosal eosinophilia and reticular basement membrane thickening in chronic obstructive pulmonary disease. Respirology. 2015;20(4):667–670. DOI:10.1111/resp.12475
   PubMed Web of Science ®Google Scholar
• Couillard S, Larivée P, Courteau J, et al. Eosinophils in COPD exacerbations are associated with increased readmissions. Chest. 2017;151(2):366–373. DOI:10.1016/j.chest.2016.10.003
   PubMed Web of Science ®Google Scholar
• Leigh R, Pizzichini MMM, Morris MM, et al. Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment. Eur Respir J. 2006;27(5):964–971. DOI:10.1183/09031936.06.00072105
   PubMed Web of Science ®Google Scholar
• Brightling CE, Bleecker ER, Panettieri RA, et al. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study. Lancet Respir Med. 2014;2(11):891–901. DOI:10.1016/S2213-2600(14)70187-0
   PubMed Web of Science ®Google Scholar
• Criner GJ, Celli BR, Brightling CE, et al. Benralizumab for the prevention of COPD exacerbations. N Engl J Med. 2019;381(11):1023–1034. DOI:10.1056/NEJMoa1905248
   PubMed Web of Science ®Google Scholar
• Dasgupta A, Kjarsgaard M, Capaldi D, et al. A pilot randomised clinical trial of mepolizumab in COPD with eosinophilic bronchitis. Eur Respir J. 2017;49(3):1602486. DOI:10.1183/13993003.02486-2016
   PubMed Web of Science ®Google Scholar
• Pavord ID, Chanez P, Criner GJ, et al. Mepolizumab for eosinophilic chronic obstructive pulmonary disease. N Engl J Med. 2017;377(17):1613–1629.
   PubMed Web of Science ®Google Scholar
• Zheng T, Zhu Z, Wang Z, et al. Inducible targeting of IL-13 to the adult lung causes matrix metalloproteinase- and cathepsin-dependent emphysema. J Clin Invest. 2000;106(9):1081–1093. DOI:10.1172/JCI10458
   PubMed Web of Science ®Google Scholar
• Wang Z, Zheng T, Zhu Z, et al. Interferon gamma induction of pulmonary emphysema in the adult murine lung. J Exp Med. 2000;192(11):1587–1600. DOI:10.1084/jem.192.11.1587
   PubMed Web of Science ®Google Scholar
• Lüthi AU, Cullen SP, McNeela EA, et al. Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity. 2009;31(1):84–98. DOI:10.1016/j.immuni.2009.05.007
   PubMed Web of Science ®Google Scholar
• Donovan C, Bourke JE, Vlahos R. Targeting the IL-33/IL-13 axis for respiratory viral infections. Trends Pharmacol Sci. 2016;37(4):252–261. DOI:10.1016/j.tips.2016.01.004
   PubMed Web of Science ®Google Scholar
• Xia J, Zhao J, Shang J, et al. Increased IL-33 expression in chronic obstructive pulmonary disease. Am J Physiol Lung Cell Mol Physiol. 2015;308(7):L619–L627. p. DOI:10.1152/ajplung.00305.2014
   PubMed Web of Science ®Google Scholar
• Rabe KF, Celli BR, Wechsler ME, et al. Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial. Lancet Respir Med. 2021;9(11):1288–1298. DOI:10.1016/S2213-2600(21)00167-3
   PubMed Web of Science ®Google Scholar
• Yousuf AJ, Mohammed S, Carr L, et al. Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease (COPD-ST2OP): a phase 2a, placebo-controlled trial. Lancet Respir Med. 2022;10(5):469–477. DOI:10.1016/S2213-2600(21)00556-7
   PubMed Web of Science ®Google Scholar
• Yadava K, Massacand J, Mosconi I, et al. Thymic stromal lymphopoietin plays divergent roles in murine models of atopic and nonatopic airway inflammation. Allergy. 2014;69(10):1333–1342. DOI:10.1111/all.12469
   PubMed Web of Science ®Google Scholar
• Shikotra A, Choy DF, Ohri CM, et al. Increased expression of immunoreactive thymic stromal lymphopoietin in patients with severe asthma. J Allergy Clin Immunol. 2012;129(1):104–111.e1-9.
   PubMed Web of Science ®Google Scholar
• Ying S, O'Connor B, Ratoff J, et al. Expression and cellular provenance of thymic stromal lymphopoietin and chemokines in patients with severe asthma and chronic obstructive pulmonary disease. J Immunol. 2008;181(4):2790–2798.
   PubMed Web of Science ®Google Scholar
• Calvén J, Yudina Y, Hallgren O, et al. Viral stimuli trigger exaggerated thymic stromal lymphopoietin expression by chronic obstructive pulmonary disease epithelium: role of endosomal TLR3 and cytosolic RIG-I-like helicases. J Innate Immun. 2012;4(1):86–99. DOI:10.1159/000329131
   PubMed Web of Science ®Google Scholar
• Rusznak C, Devalia JL, Sapsford RJ, et al. Ozone-induced mediator release from human bronchial epithelial cells in vitro and the influence of nedocromil sodium. Eur Respir J. 1996;9(11):2298–2305. DOI:10.1183/09031936.96.09112298
   PubMed Web of Science ®Google Scholar
• Lucey EC, Keane J, Kuang P-P, et al. Severity of Elastase-Induced emphysema is decreased in tumor necrosis factor-α and interleukin-1β Receptor-Deficient mice. Lab Invest. 2002;82(1):79–85. DOI:10.1038/labinvest.3780397
   PubMed Web of Science ®Google Scholar
• Lappalainen U, Whitsett JA, Wert SE, et al. Interleukin-1beta causes pulmonary inflammation, emphysema, and airway remodeling in the adult murine lung. Am J Respir Cell Mol Biol. 2005;32(4):311–318. DOI:10.1165/rcmb.2004-0309OC
   PubMed Web of Science ®Google Scholar
• Castro P, Legora-Machado A, Cardilo-Reis L, et al. Inhibition of interleukin-1beta reduces mouse lung inflammation induced by exposure to cigarette smoke. Eur J Pharmacol. 2004;498(1-3):279–286.
   PubMed Web of Science ®Google Scholar
• Churg A, Zhou S, Wang X, et al. The role of interleukin-1beta in murine cigarette smoke-induced emphysema and small airway remodeling. Am J Respir Cell Mol Biol. 2009;40(4):482–490. DOI:10.1165/rcmb.2008-0038OC
   PubMed Web of Science ®Google Scholar
• Calverley PMA, Sethi S, Dawson M, et al. A randomised, placebo-controlled trial of anti-interleukin-1 receptor 1 monoclonal antibody MEDI8968 in chronic obstructive pulmonary disease. Respir Res. 2017;18(1):153. DOI:10.1186/s12931-017-0633-7
   PubMedGoogle Scholar
• Safety and Efficacy of Multiple Doses of Canakinumab (ACZ885) in Chronic Obstructive Pulmonary Disease (COPD) Patients [Inter- net]. [cited 2022 2022/10/12]; Available from: https://clinicaltrials.gov/ct2/show/results/NCT00581945.
   Google Scholar